INNPF.US InnoCan Pharma Corporation

Consumer Defensive Pharmaceuticals USA Stocks
1.29 USD
Close of Oct 28, 2026
1.25 12.65
Market cap
USD 5.80M
P/E
-
P/B
1.21x
ROE
-41.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is INNPF.US undervalued?

Graham number

The Graham number of InnoCan Pharma Corporation cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

InnoCan Pharma Corporation fundamental analysis

No fundamental analysis for InnoCan Pharma Corporation yet.

InnoCan Pharma Corporation stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About InnoCan Pharma Corporation

InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. The company operates through two segments, Online sales and Other Operations. The company develops a cannabidiol (CBD)-loaded liposome drug delivery platform (CBD-LPT), which is in the preclinical trial phase to treat chronic pain management for human and veterinary health sectors. It also offers a pain-relieving topical composition, as well as co…

Full company profile